Targeting Pyk2 for therapeutic intervention

Christopher A. Lipinski, Joseph C Loftus

Research output: Contribution to journalArticle

66 Citations (Scopus)

Abstract

Importance of the field: The focal adhesion tyrosine kinases FAK and Pyk2 are uniquely situated to act as critical mediators for the activation of signaling pathways that regulate cell migration, proliferation and survival. By coordinating adhesion and cytoskeletal dynamics with survival and growth signaling, FAK and Pyk2 represent molecular therapeutic targets in cancer as malignant cells often exhibit defects in these processes. Areas covered in this review: This review examines the structure and function of the focal adhesion kinase Pyk2 and intends to provide a rationale for the employment of modulating strategies that include both catalytic and extra-catalytic approaches that have been developed in the last 3 5 years. What the reader will gain: Targeting tyrosine kinases in oncology has focused on the ATP binding pocket as means to inhibit catalytic activity and downregulate pathways involved in tumor invasion. This review discusses the available catalytic inhibitors and compares them to the alternative approach of targeting proteinprotein interactions that regulate kinase activity. Take home message: Development of specific catalytic inhibitors of the focal adhesion kinases has improved but significant challenges remain. Thus, approaches that inhibit the effector function of Pyk2 by targeting regulatory modules can increase specificity and will be a welcome asset to the therapeutic arena.

Original languageEnglish (US)
Pages (from-to)95-108
Number of pages14
JournalExpert Opinion on Therapeutic Targets
Volume14
Issue number1
DOIs
StatePublished - Jan 2010
Externally publishedYes

Fingerprint

Focal Adhesion Protein-Tyrosine Kinases
Protein-Tyrosine Kinases
Adhesion
Oncology
Cell Movement
Tumors
Catalyst activity
Neoplasms
Cell Survival
Phosphotransferases
Therapeutics
Down-Regulation
Adenosine Triphosphate
Chemical activation
Cell Proliferation
Defects
Growth

Keywords

  • Adhesion
  • Focal adhesion kinase
  • Glioma
  • Inhibitors
  • Invasion
  • Migration
  • Pyk2
  • Tyrosine kinases

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology
  • Clinical Biochemistry
  • Molecular Medicine

Cite this

Targeting Pyk2 for therapeutic intervention. / Lipinski, Christopher A.; Loftus, Joseph C.

In: Expert Opinion on Therapeutic Targets, Vol. 14, No. 1, 01.2010, p. 95-108.

Research output: Contribution to journalArticle

Lipinski, Christopher A. ; Loftus, Joseph C. / Targeting Pyk2 for therapeutic intervention. In: Expert Opinion on Therapeutic Targets. 2010 ; Vol. 14, No. 1. pp. 95-108.
@article{20809a49e48647bfa66bca41210e5264,
title = "Targeting Pyk2 for therapeutic intervention",
abstract = "Importance of the field: The focal adhesion tyrosine kinases FAK and Pyk2 are uniquely situated to act as critical mediators for the activation of signaling pathways that regulate cell migration, proliferation and survival. By coordinating adhesion and cytoskeletal dynamics with survival and growth signaling, FAK and Pyk2 represent molecular therapeutic targets in cancer as malignant cells often exhibit defects in these processes. Areas covered in this review: This review examines the structure and function of the focal adhesion kinase Pyk2 and intends to provide a rationale for the employment of modulating strategies that include both catalytic and extra-catalytic approaches that have been developed in the last 3 5 years. What the reader will gain: Targeting tyrosine kinases in oncology has focused on the ATP binding pocket as means to inhibit catalytic activity and downregulate pathways involved in tumor invasion. This review discusses the available catalytic inhibitors and compares them to the alternative approach of targeting proteinprotein interactions that regulate kinase activity. Take home message: Development of specific catalytic inhibitors of the focal adhesion kinases has improved but significant challenges remain. Thus, approaches that inhibit the effector function of Pyk2 by targeting regulatory modules can increase specificity and will be a welcome asset to the therapeutic arena.",
keywords = "Adhesion, Focal adhesion kinase, Glioma, Inhibitors, Invasion, Migration, Pyk2, Tyrosine kinases",
author = "Lipinski, {Christopher A.} and Loftus, {Joseph C}",
year = "2010",
month = "1",
doi = "10.1517/14728220903473194",
language = "English (US)",
volume = "14",
pages = "95--108",
journal = "Expert Opinion on Therapeutic Targets",
issn = "1472-8222",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Targeting Pyk2 for therapeutic intervention

AU - Lipinski, Christopher A.

AU - Loftus, Joseph C

PY - 2010/1

Y1 - 2010/1

N2 - Importance of the field: The focal adhesion tyrosine kinases FAK and Pyk2 are uniquely situated to act as critical mediators for the activation of signaling pathways that regulate cell migration, proliferation and survival. By coordinating adhesion and cytoskeletal dynamics with survival and growth signaling, FAK and Pyk2 represent molecular therapeutic targets in cancer as malignant cells often exhibit defects in these processes. Areas covered in this review: This review examines the structure and function of the focal adhesion kinase Pyk2 and intends to provide a rationale for the employment of modulating strategies that include both catalytic and extra-catalytic approaches that have been developed in the last 3 5 years. What the reader will gain: Targeting tyrosine kinases in oncology has focused on the ATP binding pocket as means to inhibit catalytic activity and downregulate pathways involved in tumor invasion. This review discusses the available catalytic inhibitors and compares them to the alternative approach of targeting proteinprotein interactions that regulate kinase activity. Take home message: Development of specific catalytic inhibitors of the focal adhesion kinases has improved but significant challenges remain. Thus, approaches that inhibit the effector function of Pyk2 by targeting regulatory modules can increase specificity and will be a welcome asset to the therapeutic arena.

AB - Importance of the field: The focal adhesion tyrosine kinases FAK and Pyk2 are uniquely situated to act as critical mediators for the activation of signaling pathways that regulate cell migration, proliferation and survival. By coordinating adhesion and cytoskeletal dynamics with survival and growth signaling, FAK and Pyk2 represent molecular therapeutic targets in cancer as malignant cells often exhibit defects in these processes. Areas covered in this review: This review examines the structure and function of the focal adhesion kinase Pyk2 and intends to provide a rationale for the employment of modulating strategies that include both catalytic and extra-catalytic approaches that have been developed in the last 3 5 years. What the reader will gain: Targeting tyrosine kinases in oncology has focused on the ATP binding pocket as means to inhibit catalytic activity and downregulate pathways involved in tumor invasion. This review discusses the available catalytic inhibitors and compares them to the alternative approach of targeting proteinprotein interactions that regulate kinase activity. Take home message: Development of specific catalytic inhibitors of the focal adhesion kinases has improved but significant challenges remain. Thus, approaches that inhibit the effector function of Pyk2 by targeting regulatory modules can increase specificity and will be a welcome asset to the therapeutic arena.

KW - Adhesion

KW - Focal adhesion kinase

KW - Glioma

KW - Inhibitors

KW - Invasion

KW - Migration

KW - Pyk2

KW - Tyrosine kinases

UR - http://www.scopus.com/inward/record.url?scp=72549093102&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=72549093102&partnerID=8YFLogxK

U2 - 10.1517/14728220903473194

DO - 10.1517/14728220903473194

M3 - Article

C2 - 20001213

AN - SCOPUS:72549093102

VL - 14

SP - 95

EP - 108

JO - Expert Opinion on Therapeutic Targets

JF - Expert Opinion on Therapeutic Targets

SN - 1472-8222

IS - 1

ER -